Olie R A, Zangemeister-Wittke U
Division of Medical Oncology, Department of Internal Medicine, University Hospital Zürich, Häldeliweg 4, CH-8044 Zürich, Switzerland.
Drug Resist Updat. 2001 Feb;4(1):9-15. doi: 10.1054/drup.2001.0181.
Despite the use of combination chemotherapy and immunotherapy, the survival rate of adult cancer patients has only moderately increased. Diminished apoptosis, due to overexpression of anti-apoptotic proteins, is involved in tumorigenesis and treatment resistance. Antisense oligonucleotides can be used to specifically inhibit unwanted gene expression and hence target the molecular basis of genetic diseases. Recently developed antisense oligonucleotides with the ability to inhibit the expression of anti-apoptotic proteins, including Bcl-2, Bcl-xL, FLIP and surviving, have been shown to facilitate tumor cell apoptosis and sensitize tumor cells to cytotoxic treatments. This suggests their use in combination with conventional treatments as an approach to more effective cancer therapy.
尽管使用了联合化疗和免疫疗法，但成年癌症患者的生存率仅适度提高。由于抗凋亡蛋白的过度表达导致的凋亡减少，参与了肿瘤发生和治疗抵抗。反义寡核苷酸可用于特异性抑制不需要的基因表达，从而靶向遗传疾病的分子基础。最近开发的具有抑制抗凋亡蛋白（包括Bcl-2、Bcl-xL、FLIP和存活蛋白）表达能力的反义寡核苷酸，已被证明可促进肿瘤细胞凋亡，并使肿瘤细胞对细胞毒性治疗敏感。这表明它们与传统治疗联合使用，可作为一种更有效的癌症治疗方法。
